SCHEMBL389036

SCHEMBL389036

CN(CCOc1ccc(CC(OCC(F)(F)F)C(=O)O)cc1)c1nc2ccccc2o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PPARG P37231 20/20 1.00
PPARA Q07869 2/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL389037 1.00 PPARG (1.00) PPARGPPARA
SCHEMBL30475600 1.00 PPARG (1.00) PPARGPPARA
SCHEMBL8007402 0.92 PPARG (0.86) PPARGPPARA
SCHEMBL7815152 0.92 PPARG (0.84) PPARGPPARA
SCHEMBL7997939 0.92 PPARG (0.84) PPARGPPARA
SCHEMBL9267167 0.89 PPARG (0.86) PPARGPPARA
SCHEMBL10211510 0.89 PPARG (0.86) PPARGPPARA
SCHEMBL13588984 0.89 PPARG (1.00) PPARGPPARA
SCHEMBL7822831 0.89 PPARG (1.00) PPARGPPARA
SCHEMBL7823360 0.89 PPARG (0.85) PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0648212-B1 BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES AS PHARMACEUTICAL SMITHKLINE BEECHAM PLC (GB) 2001-10-24 EP claimed
US-9724322-B2 4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs JANSSEN PHARMACEUTICA N.V. (BE) 2017-08-08 US disclosed
US-20160199342-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS CYMABAY THERAPEUTICS, INC. 2016-07-14 US disclosed
US-9034852-B2 Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators JANSSEN PHARMACEUTICA N.V. (BE) 2015-05-19 US disclosed
US-8796313-B2 Substituted dihydroisoindolones as allosteric modulators of glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2014-08-05 US disclosed
US-8580832-B2 Substituted phenoxy aminothiazolones as estrogen related receptor-α modulators JANSSEN PHARMACEUTICA N.V. (BE) 2013-11-12 US disclosed
US-8486621-B2 Nucleic acid-based matrixes CORNELL RESEARCH FOUNDATION, INC. (US) 2013-07-16 US disclosed
US-8426604-B2 Aminothiazolones as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV (BE) 2013-04-23 US disclosed
US-8242173-B2 modulators of peroxisome proliferator activated receptors; treating diabetes, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cardiovascular diseases; dyslipidema; [4-[[2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]-acetic acid JANSSEN PHARMACEUTICA N.V. (BE) 2012-08-14 US disclosed
US-20120108571-A1 SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS GAUL MICHAEL (US) 2012-05-03 US disclosed
US-6265401-B1 ANTIDIABETIC AGENTS REDDY-CHEMINOR, INC. 2001-07-24 US disclosed
US-6166049-A Use of an antagonist of PPARα and PPARγ for the treatment of syndrome X SMITHKLINE BEECHAM P.L.C. (GB) 2000-12-26 US disclosed
US-6103907-A ALDOSE REDUCTASE INHIBITING ANTIDIABETIC AGENT SANKYO COMPANY, LIMITED (JP) 2000-08-15 US disclosed
CN-1219927-A Phenylalkylcarboxylic acid derivatives SANKYO CO (JP) 1999-06-16 CN disclosed
EP-0916651-A1 PHENYLALKYLCARBOXYLIC ACID DERIVATIVES Sankyo Company, Limited (JP) 1999-05-19 EP disclosed
EP-0879053-A1 USE OF AN ANTAGONIST OF PPAR-ALPHA AND PPAR-GAMMA FOR THE TREATMENT OF SYNDROM X SMITHKLINE BEECHAM PLC (GB) 1998-11-25 EP disclosed
WO-1997025042-A1 USE OF AN AGONIST OF PPAR-ALPHA AND PPAR-GAMMA FOR THE TREATMENT OF SYNDROM X SMITHKLINE BEECHAM P.L.C. (GB) 1997-07-17 WO disclosed
EP-0772605-A1 BENZOXAZOLES AND PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF THE TYPE II DIABETES SMITHKLINE BEECHAM PLC (GB) 1997-05-14 EP disclosed
WO-1996004261-A1 BENZOXAZOLES AND PRYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF THE TYPE II DIABETES SMITHKLINE BEECHAM PLC (GB) 1996-02-15 WO disclosed
WO-1996004260-A1 BENZOXAZOLES AND PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF THE TYPE II DIABETES SMITHKLINE BEECHAM PLC (GB) 1996-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108571-A1 SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS ESR2, ESRRA, ESRRG PPARG 9/4885PPARA 33/4885
US-20160199342-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS PPARA, PPARG, PPARD PPARG 2/4885PPARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.